Dr. Reddy’s Laboratories (NYSE:RDY – Get Rating) was upgraded by equities researchers at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, The Fly reports.
Several other research firms also recently commented on RDY. JPMorgan Chase & Co. began coverage on shares of Dr. Reddy’s Laboratories in a research note on Monday, January 30th. They set an “underweight” rating on the stock. StockNews.com initiated coverage on shares of Dr. Reddy’s Laboratories in a report on Thursday. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Dr. Reddy’s Laboratories presently has a consensus rating of “Hold” and an average price target of $67.00.
Dr. Reddy’s Laboratories Trading Up 1.7 %
RDY stock opened at $55.12 on Friday. The company has a market capitalization of $9.18 billion, a PE ratio of 20.41, a price-to-earnings-growth ratio of 0.56 and a beta of 0.48. Dr. Reddy’s Laboratories has a one year low of $49.59 and a one year high of $58.28. The company’s 50 day moving average price is $53.87 and its two-hundred day moving average price is $53.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.72 and a current ratio of 2.30.
Institutional Inflows and Outflows
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations.
- Get a free copy of the StockNews.com research report on Dr. Reddy’s Laboratories (RDY)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.